7T MRI Ferumoxytol-Enhanced Characterization of Multiple Sclerosis and Demyelinating Diseases
Phase of Trial: Phase IV
Latest Information Update: 18 Oct 2016
At a glance
- Drugs Ferumoxytol (Primary) ; Gadolinium-containing contrast agents
- Indications Multiple sclerosis
- Focus Diagnostic use
- 12 Oct 2016 Planned End Date changed from 1 Jun 2015 to 1 Jun 2017.
- 12 Oct 2016 Planned primary completion date changed from 1 Jun 2015 to 1 Jun 2017.
- 01 Jul 2015 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.